April 9 (Reuters) - Eurofins Scientific SE:
* EUROFINS TECHNOLOGIES LAUNCHES MULTIPLE NEW PRODUCTS FOR SEROLOGIC DETECTION OF ANTIBODIES IN PATIENTS WHO HAVE BEEN EXPOSED TO COVID-19
* ANNOUNCES THE LAUNCH OF A RANGE OF TESTING KITS FOR SEROLOGY-BASED ANTIBODY DETECTION BY ELISA OF PATIENTS WHO HAVE BEEN EXPOSED TO COVID-19
* VIRACOR EUROFINS RECEIVED FDA EUA FOR RT-PCR SARS-COV-2 VIRUS LDT
* EUROFINS GENOMICS EXPANDS CAPACITY FOR PROBES AND PRIMERS PRODUCTION FOR RT-PCR SARS-COV-2 TEST KITS
* THE FIRST ELISA ASSAYS ARE EXPECTED TO RECEIVE CE-IVD MARK BY 16 APRIL 2020 AND WILL ALSO BE SUBMITTED TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR EMERGENCY USE AUTHORISATION
* EUROFINS GENOMICS’ SIX OLIGONUCLEOTIDES PRODUCTION SITES IN THE U.S., EUROPE, INDIA AND JAPAN ARE INCREASING THEIR CAPACITY TO PRODUCE PROBES, PRIMERS AND POSITIVE CONTROLS Source text for Eikon: Further company coverage: (Gdansk Newsroom)
Our Standards: The Thomson Reuters Trust Principles.